Analysts See $-0.67 EPS for Aimmune Therapeutics, Inc. (AIMT); Hudson Global (HSON) Has 1.08 Sentiment

April 13, 2018 - By Marie Mckinney

Hudson Global, Inc (NASDAQ:HSON) Logo

Analysts expect Aimmune Therapeutics, Inc. (NASDAQ:AIMT) to report $-0.67 EPS on May, 14.They anticipate $0.15 EPS change or 28.85% from last quarter’s $-0.52 EPS. After having $-0.81 EPS previously, Aimmune Therapeutics, Inc.’s analysts see -17.28% EPS growth. The stock increased 0.08% or $0.03 during the last trading session, reaching $31.45. About 183,101 shares traded. Aimmune Therapeutics, Inc. (NASDAQ:AIMT) has risen 29.28% since April 13, 2017 and is uptrending. It has outperformed by 17.73% the S&P500.

Hudson Global Inc (HSON) investors sentiment increased to 1.08 in 2017 Q4. It’s up 0.08, from 1 in 2017Q3. The ratio increased, as 14 investment professionals started new or increased stock positions, while 13 sold and reduced positions in Hudson Global Inc. The investment professionals in our database now have: 18.93 million shares, up from 18.67 million shares in 2017Q3. Also, the number of investment professionals holding Hudson Global Inc in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 5 Reduced: 8 Increased: 7 New Position: 7.

Among 4 analysts covering Aimmune Therapeutics (NASDAQ:AIMT), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aimmune Therapeutics had 5 analyst reports since August 31, 2015 according to SRatingsIntel. The company was initiated on Monday, August 31 by Credit Suisse. Piper Jaffray maintained Aimmune Therapeutics, Inc. (NASDAQ:AIMT) rating on Tuesday, November 17. Piper Jaffray has “Overweight” rating and $38.0 target. The firm has “Mkt Outperform” rating by JMP Securities given on Monday, September 26. The company was initiated on Monday, August 31 by Bank of America. Piper Jaffray initiated it with “Overweight” rating and $35 target in Monday, August 31 report.

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. The company has market cap of $1.82 billion. The Company’s lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. It currently has negative earnings. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics.

The stock decreased 1.02% or $0.02 during the last trading session, reaching $1.95. About 14,232 shares traded. Hudson Global, Inc (HSON) has risen 65.00% since April 13, 2017 and is uptrending. It has outperformed by 53.45% the S&P500.

Hudson Global, Inc. provides professional-level recruitment and related talent solutions for small to large-sized firms and government agencies worldwide. The company has market cap of $60.76 million. The firm offers permanent recruitment services; and contracting services, such as project management, interim management, and professional contract staffing services. It currently has negative earnings. It also offers permanent and contracting outsourced recruitment solutions, such as complete recruitment outsourcing, project outsourcing, contingent workforce, and recruitment consulting services to multinational companies; and talent management solutions, including talent assessment, interview training, executive coaching, employee development, and outplacement.

Hudson Global, Inc (NASDAQ:HSON) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>